W66C (p.Trp66Cys) variant of NFKBIA (NF-kappa-B inhibitor alpha)

W66C (p.Trp66Cys) in NFKBIA (NF-kappa-B inhibitor alpha) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.52 / 1. The record also includes population frequency data and structural context.

W66C (p.Trp66Cys) variant details